Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- 1 June 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (7), 763-774
- https://doi.org/10.1016/s1470-2045(15)00021-2
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic OpportunitiesClinical Cancer Research, 2012
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 MutationsClinical Cancer Research, 2012
- Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trialsAnnals of Oncology, 2012
- Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studiesExpert Opinion on Drug Safety, 2011
- Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)The Oncologist, 2010
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyClinical and Experimental Immunology, 2009
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scaleCancer, 1994
- EuroQol©: health-related quality of life measurement. Valuations of health states by the general public in NorwayHealth Policy, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958